Business Context and Reporting Period
Company: BioCardia, Inc. (BCDA)
Filing Type: Form 10-Q (Unaudited)
Period: Quarter and six months ended June 30, 2024
Business Overview: BioCardia is a clinical-stage company developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Key programs include the CardiAMP autologous cell therapy for heart failure and chronic myocardial ischemia, and the CardiALLO allogeneic mesenchymal stem cell therapy. The company also partners on its Helix biotherapeutic delivery system and commercializes Morph access devices.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6M 2024 | 6M 2023 |
|---|---|---|---|---|
| Revenue | $3 | $43 | $58 | $107 |
| Net Loss | $(1,646) | $(3,424) | $(3,913) | $(6,925) |
| Net Loss Per Share (Basic/Diluted) | $(0.88) | $(2.52) | $(2.20) | $(5.12) |
| Cash and Cash Equivalents (End of Period) | $1,421 | $4,305 | $1,421 | $4,305 |
| Accumulated Deficit | $(156,088) | $(147,529) | $(156,088) | $(147,529) |
| Operating Cash Flow (6M) | $(2,842) | $(5,711) | $(2,842) | $(5,711) |
| Financing Cash Flow (6M) | $3,163 | $2,665 | $3,163 | $2,665 |
Liquidity: As of June 30, 2024, the company held $1.4 million in cash. Management states this is insufficient to fund operations through September 2024 without additional capital.
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue dropped significantly to $3,000 in Q2 2024 from $43,000 in Q2 2023, attributed to the variable timing of partner development activities.
- Expense Reduction: Research and Development (R&D) expenses decreased to $800,000 in Q2 2024 from $2.3 million in Q2 2023. Selling, General, and Administrative (SG&A) expenses fell to $852,000 from $1.2 million. These reductions were driven by clinical staff reductions and personnel realignment following the completion of enrollment in the CardiAMP Heart Failure Trial in late 2023.
- Improved Loss Profile: The net loss narrowed substantially year-over-year due to the aforementioned expense cuts, despite lower revenue.
- Capital Raising: The company raised approximately $3.2 million in net financing proceeds during the first six months of 2024, primarily through At-The-Market (ATM) offerings and a private placement in February 2024.
Outlook, Risks, and Management Commentary
- Going Concern Warning: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern beyond one year. Management believes current cash is insufficient to meet obligations through September 2024.
- Funding Requirements: The company plans to raise additional capital via equity, debt, or non-dilutive collaborations. A Form S-1 registration statement was filed in August 2024 for a potential offering of common stock and warrants.
- Nasdaq Compliance: The company is working to regain compliance with Nasdaq listing standards, specifically regarding minimum market value and stockholders' equity, with a compliance deadline of September 2, 2024. Failure to comply could result in delisting.
- Clinical Progress:
- CardiAMP Heart Failure: Final dataset lock expected in Q4 2024; results expected in October 2024.
- CardiAMP Chronic Myocardial Ischemia: Phase III trial enrollment is ongoing.
- CardiALLO: Phase I/II trial for heart failure is actively enrolling.
- Reverse Stock Split: A 1-for-15 reverse stock split was effected on May 30, 2024, to assist with Nasdaq compliance.
Investor Verification Checklist
- Cash Runway: Verify the timeline and certainty of the planned capital raise to fund operations beyond September 2024.
- Nasdaq Status: Monitor the company's ability to meet the September 2, 2024, deadline for stockholders' equity compliance to avoid delisting.
- Clinical Data: Await the October 2024 release of final CardiAMP Heart Failure trial data, which is critical for future regulatory submissions.
- Dilution Risk: Assess the potential dilution from the pending Form S-1 offering and ongoing ATM sales.
- Revenue Sustainability: Evaluate the volatility of collaboration revenue, which is dependent on third-party partner milestones.